Showing results (11-20 of 120) with videos related to
Sort By:
Pageof 12
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 10, 2023
Alpelisib Efficacy without Cherry-PI3King MutationsSteven Tau, Todd W MillerCancer Metastasis Reviews|January 25, 2023
The role of cancer cell bioenergetics in dormancy and drug resistanceSteven Tau, Todd W MillerPlos One|November 26, 2019
Statistical determination of synergy based on Bliss definition of drugs independenceEugene Demidenko, Todd W MillerPlos One|January 5, 2012
Bifunctional anti-huntingtin proteasome-directed intrabodies mediate efficient degradation of mutant huntingtin exon 1 protein fragmentsDavid C Butler, Anne MesserBrain Research. Developmental Brain Research|September 8, 2004
Early postnatal Purkinje cells from staggerer mice undergo aberrant development in vitro with characteristic morphologic and gene expression abnormalitiesL Thomas Shirley, Anne MesserNeurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|May 8, 2013
Intrabodies as neuroprotective therapeuticsAnne Messer, Shubhada N JoshiBrain Research. Molecular Brain Research|February 19, 2004
A single-chain Fv intrabody provides functional protection against the effects of mutant protein in an organotypic slice culture model of Huntington's diseaseRobert C Murphy, Anne MesserNeurobiology of Disease|November 1, 2019
Optimizing intracellular antibodies (intrabodies/nanobodies) to treat neurodegenerative disordersAnne Messer, David C ButlerPharmacogenomics and Personalized Medicine|September 11, 2014
Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathwaysSarah R Hosford, Todd W MillerMolecular & Cellular Oncology|June 17, 2016
The PREX1/Rac signaling axis: Potential as a biomarker and therapeutic target in breast cancerLloye M Dillon, Todd W MillerPageof 12